Analyst Reco. AxoGen, Inc.

Equities

AXGN

US05463X1063

Market Closed - Nasdaq Other stock markets 04:00:00 2024-07-02 pm EDT			5-day change	1st Jan Change
7.52 ^USD	-2.46%		+3.30%	+10.10%

Jul. 01	Raymond James Initiates AxoGen at Outperform With $13 Price Target	MT
Jun. 24	Axogen, Inc. Announces Full Launch of Avive+ Soft Tissue Matrix	CI

Analyst Reco.

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Raymond James Initiates AxoGen at Outperform With $13 Price Target	Jul. 01	MT
Jefferies Assumes AxoGen at Buy With $15 Price Target	22-11-11	MT
Cantor Fitzgerald Adjusts AxoGen Price Target to $18 From $20, Maintains Overweight Rating	22-11-08	MT
Canaccord Genuity Upgrades AxoGen to Buy from Hold, Adjusts Price Target to $15 from $10	22-05-09	MT
SVB Leerink Adjusts AxoGen's Price Target to $14 from $12, Keeps Outperform Rating	22-05-05	MT
JMP Securities Adjusts Price Target on AxoGen to $20 from $25, Keeps Market Outperform Rating	21-11-04	MT
AXOGEN : Canaccord Genuity Adjusts AxoGen PT to $24 From $21, Maintains Hold Rating	21-05-06	MT
AXOGEN : SVB Leerink Adjusts AxoGen's Price Target to $27 From $23, Keeps Outperform Rating	21-02-23	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Protect and grow your investments with the help of our experts

Securing my Investments

fermer